Market Cap 81.67B
Revenue (ttm) 40.10B
Net Income (ttm) 3.29B
EPS (ttm) N/A
PE Ratio 9.50
Forward PE 9.23
Profit Margin 8.21%
Debt to Equity Ratio 1.21
Volume 3,403,600
Avg Vol 5,052,018
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 86%
Beta 0.51
Analysts Hold
Price Target $39.39

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 8047 5000
Website: www.gsk.com
Address:
79 New Oxford Street, London, United Kingdom
biolover
biolover Aug. 23 at 2:31 AM
$MRK Verona was a stupid waste of $10 B on a nebulizer. While the drug works, that patent relies on polymorphs special mix and can be duplicated. $GSK coming to you. Moving from kytruda cancer defeated into a nebulizer. What a shame . Whole incompetent management needs re hauled CEO has no medical background and Dean Li consider deals personal victories
0 · Reply
GreenSharken
GreenSharken Aug. 22 at 5:49 PM
$DVAX Considering Hepsilav's market potential, Chat GPT values Dynavax between 3.4B and 5.7B expecting an aquisition fight between $MRK , $GSK , $SNY and $PFE around 2028
0 · Reply
ZacksResearch
ZacksResearch Aug. 22 at 3:13 PM
GSK vs. $BMY — Which pharma giant is the better bet? 💊 $GSK's strong 18.5% YTD gain contrasts with $BMY's 14.3% decline. With the approval of new treatments and strong HIV and oncology segments, GSK is set to maintain top-line momentum. Meanwhile, BMY battles generic competition despite a robust growth portfolio. Discover why GSK may be the smarter choice now 👉 https://www.zacks.com/stock/news/2741619/bmy-vs-gsk-which-biopharma-bigwig-has-better-prospects-for-now?cid=sm-stocktwits-2-2741619-body-9086&ADID=SYND_STOCKTWITS_TWEET_2_2741619_BODY_9086
0 · Reply
ZacksResearch
ZacksResearch Aug. 22 at 2:13 PM
$BMY vs $GSK — which biopharma giant wins now? Bristol Myers is banking on fresh launches to replace fading blockbusters, while GSK’s diversified portfolio and strong HIV franchise are driving steady growth. Full matchup breakdown here 👉 https://www.zacks.com/stock/news/2741619/bmy-vs-gsk-which-biopharma-bigwig-has-better-prospects-for-now?cid=sm-stocktwits-2-2741619-teaser-9085&ADID=SYND_STOCKTWITS_TWEET_2_2741619_TEASER_9085
1 · Reply
greedy_ticker
greedy_ticker Aug. 22 at 2:52 AM
$GSK Pharma company focused on vaccines and HIV post consumer health spin off pipeline execution is key to overcoming patent cliffs and driving growth
0 · Reply
look2theblue
look2theblue Aug. 22 at 2:48 AM
$ITRM approval of those shares DOES NOT = DILUTION, that only comes IF he sells those shares. But it does give him a $80M credit line which he could choose to use to ramp the launch further. That may not be favorable to any acquirer that was looking to buy Orlynvah on the cheap. Suddenly that $1/share offer $PFE or $GSK made, might have to be raised to $3. Corey strikes me as poker player. Now if he'd only buy some shares.
2 · Reply
Quantumup
Quantumup Aug. 21 at 3:41 PM
Canaccord Genuity y'day reit'd $WVE Buy/$19: $WVE plans to report updated Ph1/2 WVE-006 [ $GSK ] data from the completed SAD and MAD 200mg cohorts this Q - we think sometime in the coming weeks (followed by 400mg SAD data "in the fall" per the co). As a reminder, SAD data from the first two patients dosed was shared in Oct 2024, showing an increase in both M-AAT (6.9uM) and total AAT (10.8uM). We're expecting positive data from the MAD cohort, given co commentary around greater liver exposure and higher liver concentration of WVE-006 with the multidose. We like the risk/reward in this update and expect ~30%+ upside on good news (for reference, shares were up ~74% from ~$9 to ~$15 on the Oct 2024 update) vs. transient ~10% downside on a disappointing update. Downside protection comes from more AATD data expected in the fall as noted above, as well as data from the (wholly owned, higher TAM) WVE-007 in the obesity program coming later in the year. Reiterate BUY. $ALNY $QURE PTCT LLY NVO $VKTX
0 · Reply
Quantumup
Quantumup Aug. 21 at 11:31 AM
Morgan Stanley🏁 $TRVI Overweight/$18. $PFE $GSK $MRK - $VRNA Morgan Stanley said: We initiate coverage of $TRVI with an OW rating and $18 price target. $TRVI is developing Haduvio, an oral, extended-release formulation of nalbuphine, a mixed opioid agonist-antagonist, for chronic cough. While perhaps seemingly innocuous, chronic cough is a debilitating condition with few treatment options that affects millions of individuals in the US. Existing therapies provide limited relief or come with serious risks (e.g., abuse potential, respiratory depression). The unmet need has caught the interest of pharma companies like GSK (covered by Sarita Kapila) and Merck (covered by Terence Flynn), which have entered into billion-dollar (incl. potential milestones) deals for compounds that can suppress chronic cough.
0 · Reply
clan
clan Aug. 21 at 6:55 AM
$MNKD Will Novartis $NVS , with its $241B market cap., have an interest to get back in the Clofazimine game? Asking for friends at $GSK and $AMGN
1 · Reply
Twinity
Twinity Aug. 20 at 5:23 AM
$NVOX $NVOH 2x funds for NOVO Nordisk See perf and market mirror movement at.. after forced bottoms.. or any other leverage fund , bulls are ok on dip buy... Bears are decaying $AZNH for 2x $AZN $GSKH for 2x $GSK Please @Stocktwits have them quoted... Thank you. Otherwise U should refer to their prospectus from Defiance fundsbor others... Could be long ... Better played in medium term cycles... As they hold options swaps and other vehicles.
0 · Reply
Latest News on GSK
GSK's antibiotic drug gepotidacin gets priority review by FDA

Aug 11, 2025, 2:15 AM EDT - 11 days ago

GSK's antibiotic drug gepotidacin gets priority review by FDA


GSK plc (GSK) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 5:56 PM EDT - 23 days ago

GSK plc (GSK) Q2 2025 Earnings Call Transcript


GSK's blood cancer drug gets EU approval for multiple myeloma

Jul 24, 2025, 12:27 PM EDT - 4 weeks ago

GSK's blood cancer drug gets EU approval for multiple myeloma


US FDA extends review of GSK's blood cancer drug

Jul 23, 2025, 12:15 PM EDT - 4 weeks ago

US FDA extends review of GSK's blood cancer drug


FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

Jul 17, 2025, 6:19 PM EDT - 5 weeks ago

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep


US FDA approves pre-filled version of GSK's shingles vaccine

Jul 17, 2025, 7:35 AM EDT - 5 weeks ago

US FDA approves pre-filled version of GSK's shingles vaccine


GSK seeks FDA nod for expanded use of RSV vaccine in adults

Jul 14, 2025, 2:42 AM EDT - 5 weeks ago

GSK seeks FDA nod for expanded use of RSV vaccine in adults


Bharat, GSK to halve price of malaria vaccine by 2028

Jun 25, 2025, 3:29 AM EDT - 2 months ago

Bharat, GSK to halve price of malaria vaccine by 2028


GSK says EU heath regulator reviewing expansion of RSV vaccine

Jun 13, 2025, 2:14 AM EDT - 2 months ago

GSK says EU heath regulator reviewing expansion of RSV vaccine


GSK's Blood-Cancer Treatment Combinations Approved in Japan

May 19, 2025, 2:41 AM EDT - 3 months ago

GSK's Blood-Cancer Treatment Combinations Approved in Japan


GSK to buy efimosfermin for up to $2 billion

May 14, 2025, 2:24 AM EDT - 3 months ago

GSK to buy efimosfermin for up to $2 billion


biolover
biolover Aug. 23 at 2:31 AM
$MRK Verona was a stupid waste of $10 B on a nebulizer. While the drug works, that patent relies on polymorphs special mix and can be duplicated. $GSK coming to you. Moving from kytruda cancer defeated into a nebulizer. What a shame . Whole incompetent management needs re hauled CEO has no medical background and Dean Li consider deals personal victories
0 · Reply
GreenSharken
GreenSharken Aug. 22 at 5:49 PM
$DVAX Considering Hepsilav's market potential, Chat GPT values Dynavax between 3.4B and 5.7B expecting an aquisition fight between $MRK , $GSK , $SNY and $PFE around 2028
0 · Reply
ZacksResearch
ZacksResearch Aug. 22 at 3:13 PM
GSK vs. $BMY — Which pharma giant is the better bet? 💊 $GSK's strong 18.5% YTD gain contrasts with $BMY's 14.3% decline. With the approval of new treatments and strong HIV and oncology segments, GSK is set to maintain top-line momentum. Meanwhile, BMY battles generic competition despite a robust growth portfolio. Discover why GSK may be the smarter choice now 👉 https://www.zacks.com/stock/news/2741619/bmy-vs-gsk-which-biopharma-bigwig-has-better-prospects-for-now?cid=sm-stocktwits-2-2741619-body-9086&ADID=SYND_STOCKTWITS_TWEET_2_2741619_BODY_9086
0 · Reply
ZacksResearch
ZacksResearch Aug. 22 at 2:13 PM
$BMY vs $GSK — which biopharma giant wins now? Bristol Myers is banking on fresh launches to replace fading blockbusters, while GSK’s diversified portfolio and strong HIV franchise are driving steady growth. Full matchup breakdown here 👉 https://www.zacks.com/stock/news/2741619/bmy-vs-gsk-which-biopharma-bigwig-has-better-prospects-for-now?cid=sm-stocktwits-2-2741619-teaser-9085&ADID=SYND_STOCKTWITS_TWEET_2_2741619_TEASER_9085
1 · Reply
greedy_ticker
greedy_ticker Aug. 22 at 2:52 AM
$GSK Pharma company focused on vaccines and HIV post consumer health spin off pipeline execution is key to overcoming patent cliffs and driving growth
0 · Reply
look2theblue
look2theblue Aug. 22 at 2:48 AM
$ITRM approval of those shares DOES NOT = DILUTION, that only comes IF he sells those shares. But it does give him a $80M credit line which he could choose to use to ramp the launch further. That may not be favorable to any acquirer that was looking to buy Orlynvah on the cheap. Suddenly that $1/share offer $PFE or $GSK made, might have to be raised to $3. Corey strikes me as poker player. Now if he'd only buy some shares.
2 · Reply
Quantumup
Quantumup Aug. 21 at 3:41 PM
Canaccord Genuity y'day reit'd $WVE Buy/$19: $WVE plans to report updated Ph1/2 WVE-006 [ $GSK ] data from the completed SAD and MAD 200mg cohorts this Q - we think sometime in the coming weeks (followed by 400mg SAD data "in the fall" per the co). As a reminder, SAD data from the first two patients dosed was shared in Oct 2024, showing an increase in both M-AAT (6.9uM) and total AAT (10.8uM). We're expecting positive data from the MAD cohort, given co commentary around greater liver exposure and higher liver concentration of WVE-006 with the multidose. We like the risk/reward in this update and expect ~30%+ upside on good news (for reference, shares were up ~74% from ~$9 to ~$15 on the Oct 2024 update) vs. transient ~10% downside on a disappointing update. Downside protection comes from more AATD data expected in the fall as noted above, as well as data from the (wholly owned, higher TAM) WVE-007 in the obesity program coming later in the year. Reiterate BUY. $ALNY $QURE PTCT LLY NVO $VKTX
0 · Reply
Quantumup
Quantumup Aug. 21 at 11:31 AM
Morgan Stanley🏁 $TRVI Overweight/$18. $PFE $GSK $MRK - $VRNA Morgan Stanley said: We initiate coverage of $TRVI with an OW rating and $18 price target. $TRVI is developing Haduvio, an oral, extended-release formulation of nalbuphine, a mixed opioid agonist-antagonist, for chronic cough. While perhaps seemingly innocuous, chronic cough is a debilitating condition with few treatment options that affects millions of individuals in the US. Existing therapies provide limited relief or come with serious risks (e.g., abuse potential, respiratory depression). The unmet need has caught the interest of pharma companies like GSK (covered by Sarita Kapila) and Merck (covered by Terence Flynn), which have entered into billion-dollar (incl. potential milestones) deals for compounds that can suppress chronic cough.
0 · Reply
clan
clan Aug. 21 at 6:55 AM
$MNKD Will Novartis $NVS , with its $241B market cap., have an interest to get back in the Clofazimine game? Asking for friends at $GSK and $AMGN
1 · Reply
Twinity
Twinity Aug. 20 at 5:23 AM
$NVOX $NVOH 2x funds for NOVO Nordisk See perf and market mirror movement at.. after forced bottoms.. or any other leverage fund , bulls are ok on dip buy... Bears are decaying $AZNH for 2x $AZN $GSKH for 2x $GSK Please @Stocktwits have them quoted... Thank you. Otherwise U should refer to their prospectus from Defiance fundsbor others... Could be long ... Better played in medium term cycles... As they hold options swaps and other vehicles.
0 · Reply
clan
clan Aug. 19 at 1:13 AM
$MNKD It is reported that only about 30% of those who should be treated with Clofazimine take their Clofazimine because the current form of the med has such severe adverse reactions; nausea, diarrhrea, and skin turning red. Since Mannkind's CIS (MNKD-101) does not have those AEs, it could be expected that Mannkind should capture the lion's share of a near $8B patient population. Holy frijoles!🌶 CLOFAZIMINE (CIS) by Mannkind ----------------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the Adverse Events caused by other pharmas' current formulations} ...and coming soon.... - - - Clofazimine DPI Partner with $GSK ? $NOV ?
1 · Reply
stockanalysis_
stockanalysis_ Aug. 17 at 12:00 AM
0 · Reply
Flowdollas
Flowdollas Aug. 15 at 2:01 PM
$NVAX All Aboard!! FOMO $GSK $PFE $MRK https://www.nature.com/articles/s41541-025-01243-5
0 · Reply
BiotechBonesaw
BiotechBonesaw Aug. 14 at 10:03 PM
$TNXP y’all need to chill out. Do some research or check ChatGPT - most drugs are approved on the PDUFA date, not before (sometimes delays will happen like with $KALV & $GSK most recently). Heck somebody just yesterday posted the list of Friday approvals in 2025 alone and there were 5 IIRC. Buy the dip if you believe and are a Tonix Pioneer, or sell if you’re a FUD. GLB 👍 ☘️ 🐂
2 · Reply
stockanalysis_
stockanalysis_ Aug. 14 at 1:17 AM
100 Oldest Publicly Traded Companies: $BUD $BCS $LYG $GSK $NWG View the entire list here: https://stockanalysis.com/list/oldest-companies/?ref=saveontrading
0 · Reply
BioRich
BioRich Aug. 13 at 8:45 PM
$VSTM. DATA DROP!!! Boooooooommmmm $XBI $PFE $GSK $LLY
0 · Reply
SnapCrackleStop
SnapCrackleStop Aug. 12 at 7:53 PM
$SCYX If $GSK pays the $10MM invoice that’s owed. The cash runway is a lot longer. $$$
1 · Reply
MedicineMan777
MedicineMan777 Aug. 12 at 6:27 PM
$GSK Want a 100x banger? new kid on the block with ketamine FDA approval taking on JNJ market share
1 · Reply
theflynews
theflynews Aug. 8 at 7:39 PM
Sector Spotlight: Trump administration seeks hometown discount from Big Pharma - $GSK - https://thefly.com/permalinks/entry.php/GSKid418021
0 · Reply
DeepSeek
DeepSeek Aug. 8 at 6:01 PM
$TNXP $BMY $MRK $GSK $TAK Tonix Pharmaceuticals represents @deepseek ing value for whales
0 · Reply
look2theblue
look2theblue Aug. 6 at 1:44 AM
$ITRM $GSK $PFE I said this months ago. Blujepa works by interfering with DNA-handling enzymes called topoisomerases (enzymes essential for DNA replication, transcription, and repair). Interfering with DNA replication raises reasonable concerns about potential off-target effects on human cells. Despite preclinical safety data I do think many patients (and some providers) will shy away from wanting anything to do with Blujepa given the terrible worldwide experience so many had with mRNA covid vaccines. I personally would not take Blujepa for the same reason I didn't want an mRNA vaccine - it's to new and I don't want someone fiddling with my DNA (remember how they told everyone it's safe and months years later we find there's issues - no thanks). I'd take a proven penem class antibiotic like Orlynvah any day over a Blujepa.
1 · Reply
n44
n44 Aug. 6 at 12:48 AM
$GSK Does anyone know what’s happening with Spero Therapeutics and Tebibenem, is there any chance of a buyout
0 · Reply